| Name | Title | Contact Details |
|---|
Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients in mainland China and other Asian territories. We strive to be the partner of choice for innovative companies around the world with products that address critical unmet medical needs for patients in Greater China and have a high probability of market approval. The Everest Medicines team has deep expertise and extensive track record of high quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. The company`s Series A round was led by C-Bridge Capital, a top-tier China healthcare private equity firm, with US $800 million under management.
Telehealth Available: Trusted Addiction Medicine serving the greater Phoenix, AZ area. Visit our website to book an appointment online: 2nd Chance Treatment Center
We are a specialty pharmaceutical company developing transformative therapies to advance the treatment of gastrointestinal (GI) disorders. We focus on developing treatments for GI disorders for which meaningful therapeutic innovation is required to satisfy unmet patient need and disease burden. Our management team and board of directors are comprised of professionals with extensive backgrounds in drug research and development, commercialization, finance and business development for leading global pharmaceutical companies and growth-stage biopharmaceutical companies. Our scientific advisory board consists of well-known gastroenterologists and clinical thought leaders. Today, our pipeline consists of two unique clinical stage therapies with the potential to bring benefit to millions of patients with chronic and debilitating GI disorders that are not adequately controlled.
Based in Princeton, New Jersey, Oyster Point Pharma is a clinical stage pharmaceutical company leveraging neuroscience to discover, develop and commercialize novel therapies to treat diseases with high unmet needs. The company`s initial focus is to develop innovative therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production. Oyster Point is leveraging a class of receptors called nicotinic acetylcholine receptors (nAChRs) which are located on the trigeminal nerve, accessible within the nose, to stimulate natural tear film production. The two lead product candidates, OC-01 and OC-02, are delivered via a nasal spray and are currently in Phase 2 trials for treatment of Dry Eye Disease (DED). Our leadership team brings extensive experience in developing and commercializing therapies for ophthalmic and other disease categories. Oyster Point is backed by industry leading investors, Versant Ventures and NEA and has an esteemed Board of Directors and Scientific and Medical Advisory Board.